CASC3 and neoplasm: Notably, the lack of BTZ-F therapeuticactivity is likely due to the relative resistance of RPMI cells toBTZ as well as the frequency at which the drug was administered, i.e.,once a week instead of twice a week usually given in mice and patients.To further assess tumor burden, bones obtained at end point were analyzedfor expression of the MM surface marker, CD138.